2025年预亏超2亿元 “常温乳酸菌第一股”均瑶健康为何失灵了？

Core Viewpoint - Junyao Health, known as the "first stock of ambient lactic acid bacteria" in A-shares, is facing significant financial challenges, with a projected net loss of between -216 million to -144 million yuan for 2025, marking a year-on-year decrease of 395.14% to 642.71% [2][15][25] Financial Performance - The company expects a substantial decline in net profit for 2025, with a projected loss of -233 million to -155 million yuan, representing a year-on-year decrease of 167.33% to 301.00% [2][15] - Since its listing in 2020, Junyao Health has experienced revenue growth, but net profit has consistently declined, showcasing a typical "increased revenue without increased profit" pattern, culminating in significant losses in 2025 [2][15][25] - Junyao Health's net profit has decreased for five consecutive years, with a reported revenue of 1.458 billion yuan in 2024, down 10.77% year-on-year, and a net profit of -29.12 million yuan, a decline of 150.57% [4][17] Factors Contributing to Losses - The anticipated losses for 2025 are attributed to several factors, including a challenging consumer environment leading to reduced market share in the dairy beverage sector, increased sales and marketing expenses, and higher research and development costs [4][17] - Significant impairment provisions for inventory and receivables, totaling an impact of 80 million to 140 million yuan, are identified as core drivers of the profit decline [4][17] - The company has previously reported substantial impairment losses, including 36.43 million yuan for goodwill and 12.76 million yuan for inventory write-downs in 2024, which have severely affected profitability [5][18] Market and Product Strategy - Junyao Health has attempted a "second entrepreneurship" strategy since 2021, focusing on upstream integration, new product launches, and diversification to mitigate reliance on single products [21] - Despite launching numerous new products since 2023, including those targeting specific consumer needs, the market response has been lukewarm, failing to generate significant sales volume or new growth points [10][23] - The company's marketing expenditures have surged, with sales expenses increasing by 30.27% to 245 million yuan in 2024 and a further 70.65% increase in the first half of 2025, which has further eroded profits [11][24] Stock Performance - Junyao Health's stock price has been on a downward trend since 2022, reaching a historical low of 4.18 yuan per share in 2024, and as of January 30, 2026, the stock price was 6.94 yuan, significantly lower than its initial offering price of 13.43 yuan [6][20] Future Outlook - Despite the current challenges, the dairy beverage industry still presents growth opportunities, with trends towards functionality, premiumization, and diversification [25][26] - Junyao Health possesses advantages in strain research and development, brand accumulation, and channel distribution, which could support a turnaround if strategic adjustments are made [25] - The company needs to focus on core business strengths, optimize product structure, and enhance cost control to gradually reverse the declining performance trend [25][26]